Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme

HealthTech approach

HealthTech approach

Advice programme

Area of interest

Showing 1 to 25 of 341

TitleReference numberPublishedLast updated
Advanced breast cancer: diagnosis and treatmentCG81
Breast cancerQS12
Mirvetuximab soravtansine for treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancerTA1169
Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancerTA1167
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy (terminated evaluation)TA1168
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancerTA1165
Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatmentTA1164
Nogapendekin alfa inbakicept with BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG (terminated evaluation)TA1163
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancerTA1158
Osimertinib for treating EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapyTA1156
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatmentTA1153
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancerTA1150
Ovarian cancerQS18
Ovarian cancer: recognition and initial managementCG122
Suspected cancer: recognition and referralNG12
Kidney cancerQS215
Kidney cancer: diagnosis and managementNG256
Artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway: early value assessmentHTG746
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer (terminated appraisal)TA1141
Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancerTA1138
Bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancerTA1136
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapyTA1129
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancerTA1130
Nivolumab with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancerTA1127
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancerTA1122

Results per page

  1. 10
  2. 25
  3. 50
  4. All